Gad Soffer - 10 Sep 2025 Form 3 Insider Report for LB PHARMACEUTICALS INC

Role: Chief Business Officer
Signature: /s/ Marc Panoff, Attorney-in-Fact
Issuer symbol: LBRX on Nasdaq
Transactions as of: 10 Sep 2025
Net transactions value: $0
Form type: 3
Filing time: 10 Sep 2025, 19:34:53 UTC
Previous filing: 13 Aug 2021
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Soffer Gad	Chief Business Officer	C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK	/s/ Marc Panoff, Attorney-in-Fact	10 Sep 2025	0001612090

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LBRX	Employee Stock Option (Right to Buy)							10 Sep 2025	Common Stock	26,893	$41.84	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.